Table 4. Differences between non-recurrence and recurrence groups (n=57).

Characteristics		Non-recurrence group (n=49)	Recurrence group (n=8)	p-value
Age (yr), median		42 (23–69)	38.5 (30–52)	0.418
Gravida, median		2 (0–4)	1 (0–4)	0.228
Parity, median		2 (0–3)	0.5 (0–3)	0.159
Tumor size (cm), median		6 (1–26)	10 (3–20)	0.160
Median follow-up (mo)		56 (25–114)	64 (16–125)	0.512
Serum CA-125 (U/mL), median		20 (4–60)	28 (17–65)	0.167
Smoking, No. (%)		12 (24.5%)	3 (37.5%)	0.531
Type of surgery, No. (%)				0.353
	TAH	11 (22.4%)	0
	TAH+BSO	13 (26.5%)	1 (12.5%)
	TAH+USO	3 (6.1%)	1 (12.5%)
	VH	1 (2%)	0
	Myomectomy	21 (42.9%)	6 (75%)
Uterine localization, No. (%)				0.002
	Intramural	37 (75.5%)	1 (12.5%)
	Subserous	7 (14.3%)	5 (62.5%)
	Submucous	5 (10.2%)	2 (25%)
Mitosis, No. (%)				0.399
	0–5	18 (36.7%)	1 (12.5%)
	5–10	26 (53.1%)	6 (75%)
	≥10	5 (10.2%)	1 (12.5%)
Cellularity				0.659
	Moderate	9 (18.4%)	2 (25%)
	High	40 (81.6%)	6 (75%)
Atypia				0.379
	Mild	11 (22.4%)	3 (37.5%)
	Mild to moderate	22 (44.9%)	1 (12.5%)
	Moderate	7 (14.3%)	2 (25%)
	Moderate to severe	9 (18.4%)	2 (25%)
Necrosis				0.783
	Absent	41 (84.2%)	7 (87.5%)
	Multifocal	8 (15.8%)	1 (12.5%)

TAH+BSO, total abdominal hysterectomy+bilateral salpingo-oophorectomy; TAH+USO, total abdominal hysterectomy+unilateral salpingo-oophorectomy; TAH, total abdominal hysterectomy; VH, vaginal hysterectomy; STUMP, uterine smooth muscle tumors of uncertain malignant potential.